By Turna Ray

CVS Caremark this week announced the 13 drugs for which the pharmacy services provider will provide pharmacogenomic testing as part of a pilot program slated for launch in July.

Although CVS Caremark is offering PGx testing for many of the drugs that competitor Medco includes in its service, one major difference is that CVS Caremark will not be offering genetic testing to gauge warfarin sensitivity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.